Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 105-111

  Xin, Zeng Feng ^a   Shen, Cheng Chun ^a   Tao, Li Jiang ^a   Yan, Shi Gui ^a   Wu, Hao Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gambogic acid; Invasion; Matrix metalloproteinase 9; Osteosarcoma; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

GAMBOGIC ACID; GELATINASE B; MESSENGER RNA; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; MATRIX METALLOPROTEINASE 9; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION; XANTHONES;

EID: 84873201002     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1192     Document Type: Article

References (32)

1. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 41: 2836-2845, 2005.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU and Flege S: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
3. Ferrari S, Briccoli A, Mercuri M, Bertoni F and Picci P: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21: 710-715, 2003.
4. Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, van Marck E and Hogendoorn PC: Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Human Genetics 11: 611-618, 2003.
5. Link MP: Preoperative and adjuvant chemotherapy in osteosarcoma. In: Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances. Novak JF and Mcmaster JH (eds). Hogrefe and Huber, Seattle, pp41-49, 1993.
6. Wolf K and Friedl P: Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis 26: 289-298, 2009.
7. Clark IM, Swingler TE, Sampieri CL and Edwards DR: The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378, 2008.
8. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
9. Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214, 2002.
10. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
11. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
12. Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178-193, 2001.
13. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET and Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59: 329-341, 1993.
14. Phillips BW, Sharma R, Leco PA and Edwards DR: A sequence-selective single-strand DNA-binding protein regulates basal transcription of the murine tissue inhibitor of metalloproteinases-1 (Timp-1) gene. J Biol Chem 274: 22197-22207, 1999.
15. Kossakowska AE, Urbanski SJ and Edwards DR: Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 77: 2475-2481, 1991.
16. Yoshiji H, Gomez DE and Thorgeirsson UP: Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer 69: 131-134, 1996.
17. Fong KM, Kida Y, Zimmerman PV and Smith PJ: TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2: 1369-1372, 1996.
18. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 127: 151-156, 2005.
19. Korpi JT, Hagström J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol 20: e18-e22, 2011.
20. Zhao W, Zhou SF, Zhang ZP, Xu GP, Li XB and Yan JL: Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep 25: 1289-1295, 2011.
21. Guo QL, You QD, Wu ZQ, Yuan ST and Zhao L: General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin 25: 769-774, 2004.
22. Yu J, Guo QL, You QD, et al: Gambogic acid-induced G(2)/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28: 632-638, 2007.
23. Kasibhatla S, Jessen KA, Maliartchouk S, et al: A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 102: 12095-12100, 2005.
24. Chen J, Gu HY, Lu N, et al: Microtubule depolymerization and phosphorylation of c-Jun n-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma McF-7 cells. Life Sci 83: 103-109, 2008.
25. Wu ZQ, Guo QL, You QD, Zhao L and Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 27: 1769-1774, 2004.
26. Guo Q, Qi Q, You Q, Gu H, Zhao L and Wu Z: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol 99: 178-184, 2006.
27. Qi Q, You Q, Gu H, et al: Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol 117: 433-438, 2008.
28. Qi Q, Lu N, Wang XT, et al: Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol 86: 386-395, 2008.
29. Zhang S, Li L, Lin JY and Lin H: Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 9: 899-904, 2003.
30. Seo YS, Park JJ, Kim JH, et al: Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci 52: 753-759, 2007.
31. Guruvayoorappan C and Kuttan G: Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol 30: 711-727, 2008.
32. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T and Hendriks T: Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 90: 1556-1564, 2003.